Go Pro
NASDAQ:MEDS

Wellgistics Health Q2 2026 Earnings Report

Wellgistics Health logo
$6.07 +4.45 (+274.69%)
As of 04:00 PM Eastern

Wellgistics Health EPS Results

Actual EPS
-$7.13
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Wellgistics Health Revenue Results

Actual Revenue
$1.78 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Wellgistics Health Announcement Details

Quarter
Q2 2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Wellgistics Health Earnings Headlines

The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this supercycle - and says that may be conservative. Billionaire Pierre Lassonde has argued for $19,000. Former CIA advisor Jim Rickards targets $27,000 based on a federal revaluation of the gold supply. But the bigger opportunity may not be gold itself. A 'backdoor' gold-linked asset has historically multiplied gold's move by 10x or more - returning 846%, 1,668%, 1,847%, and 1,915% in the last supercycle.tc pixel
See More Wellgistics Health Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Wellgistics Health? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Wellgistics Health and other key companies, straight to your email.

About Wellgistics Health

Wellgistics Health (NASDAQ:MEDS) is a healthcare technology and pharmaceutical services company focused on improving access to prescription medications in the United States. The company works across the healthcare supply chain to connect pharmaceutical manufacturers, healthcare providers, pharmacies and patients through technology-enabled distribution and support services.

Its offerings include pharmaceutical distribution and related services designed to help independent pharmacies and other healthcare organizations obtain and dispense prescription medicines. Wellgistics has also highlighted solutions supporting specialty and high-demand therapies, including medications used in diabetes and weight-management treatment, subject to applicable regulatory and prescribing requirements.

The company’s business is primarily focused on the U.S. healthcare market. Wellgistics Health’s operations include its Wellgistics Rx platform and related technology and fulfillment capabilities, which are intended to streamline medication access, ordering and delivery for participating pharmacies and providers. Publicly available information about its broader operating history and leadership is limited.

View Wellgistics Health Profile